Feb 13 (Reuters)- Taiko Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Dec 31, 2025 Dec 31, 2024 Dec 31, 2026 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 6.40 6.29 7.20 (+1.7 pct) (+2.8 pct) (+12.5 pct) Operating 459 mln 629 mln 500 mln (-27.1 pct) (+8.9 pct) Recurring 482 mln 688 mln 520 mln (-29.8 pct) (+7.7 pct) Net Net 923 mln 898 mln 550 mln (+2.8 pct) (-40.4 pct) EPS 18.38 yen 17.90 yen 10.95 yen Ann Div 3.30 yen NIL 3.50 yen -Q2 Div NIL NIL NIL -Q4 Div 3.30 yen NIL 3.50 yen NOTE - Taiko Pharmaceutical Co Ltd. *Second Net profit row denotes profit attributable to owners ofthe parent To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4574.T